| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Aug 11, 2020 | COLL Collegium Pharmaceutical, Inc | Heffernan Michael Thomas | Director | Sell | 13,071 | $19.13 | $250,048.23 | -19.5% | |
| Aug 11, 2020 | BCRX Biocryst Pharmaceuticals Inc | Doyle Anthony70 | Chief Financial Officer | Buy | 54,000 | $4.08 | $220,320.00 | New | |
| Aug 10, 2020 | ANIP Ani Pharmaceuticals Inc | Walsh Patrick D52 | Chairman, Interim Pres. &CEO | Buy | 10,000 | $30.78 | $307,790.00 | +14.2% | |
| Aug 10, 2020 | EBS Emergent Biosolutions Inc. | Zoon Kathryn C62 | Director | Sell | 1,000 | $130.27 | $130,270.00 | -7.4% | |
| Aug 7, 2020 | CRON Cronos Group Inc. | Abraham Todd Kevin | Chief Innovation Officer | Buy | 15,000 | $5.78 | $86,755.50 | New | |
| Aug 7, 2020 | EBS Emergent Biosolutions Inc. | Richard Ronald | Director | Sell | 6,297 | $131.00 | $824,907.00 | -43.2% | |
| Aug 7, 2020 | BUDZ Weed, Inc. | Breen Nicole M | Secretary/ Treasurer | Sell | 24,000 | $0.26 | $6,291.50 | - | |
| Aug 6, 2020 | PFE Pfizer Inc | Blaylock Ronald E | Director | Buy | 13,000 | $38.55 | $501,085.00 | +29.9% | |
| Aug 6, 2020 | ELAN Elanco Animal Health Inc | Garcia Art A45 | Director | Buy | 2,000 | $24.76 | $49,520.00 | +28.3% | |
| Aug 5, 2020 | MRK Merck & Co., Inc. | Clyburn Frank | EVP, Chief Commercial Officer | Sell | 18,876 | $81.55 | $1,539,273.62 | -18.9% | |
| Aug 5, 2020 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 2,257 | $118.87 | $268,285.53 | -2.3% | |
| Aug 5, 2020 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 2,257 | $118.83 | $268,199.76 | -2.8% | |
| Aug 5, 2020 | NBIX Neurocrine Biosciences Inc | Abernethy Matt57 | Chief Financial Officer | Sell | 2,257 | $118.90 | $268,355.95 | -22.0% | |
| Aug 5, 2020 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 2,257 | $118.87 | $268,297.26 | -7.4% | |
| Aug 5, 2020 | NBIX Neurocrine Biosciences Inc | Bozigian Haig P. | Chief Development Officer | Sell | 2,257 | $118.89 | $268,324.35 | -1.5% | |
| Aug 5, 2020 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 2,257 | $118.85 | $268,254.16 | -12.8% | |
| Aug 5, 2020 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 3,390 | $118.91 | $403,101.17 | -0.8% | |
| Aug 5, 2020 | NBIX Neurocrine Biosciences Inc | Lloyd-Smith Malcolm49 | Chief Regulatory Officer | Sell | 2,257 | $118.86 | $268,277.40 | -7.7% | |
| Aug 5, 2020 | NBIX Neurocrine Biosciences Inc | Cooke Julie59 | Chief Human Resources Officer | Sell | 2,257 | $118.91 | $268,382.80 | -20.7% | |
| Aug 5, 2020 | NBIX Neurocrine Biosciences Inc | Roberts Eiry49 | Chief Medical Officer | Sell | 2,257 | $118.84 | $268,225.27 | -16.5% | |
| Aug 3, 2020 | TLRY Tilray Brands, Inc. | Auerbach Michael | Director | Sell | 355,134 | $7.27 | $2,583,597.60 | -56.4% | |
| Aug 3, 2020 | TLRY Tilray Brands, Inc. | Greenwood Maryscott | Director | Sell | 5,000 | $7.27 | $36,370.00 | -20.7% | |
| Aug 3, 2020 | ZTS Zoetis Inc. | Chen Heidi C.47 | Executive Vice President | Sell | 1,179 | $152.19 | $179,432.01 | -6.7% | |
| Aug 3, 2020 | PCRX Pacira Biosciences, Inc. | Laranjeira Charles Anthony61 | SVP, Technical Operations | Sell | 2,500 | $52.68 | $131,700.00 | -10.7% | |
| Aug 3, 2020 | ELAN Elanco Animal Health Inc | Young Todd S. | See Remarks | Buy | 7,000 | $23.91 | $167,400.00 | New |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.